216 related articles for article (PubMed ID: 29777191)
1. Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter.
Shimizu K; Soroida Y; Sato M; Hikita H; Kobayashi T; Endo M; Sato M; Gotoh H; Iwai T; Tateishi R; Koike K; Yatomi Y; Ikeda H
Sci Rep; 2018 May; 8(1):7845. PubMed ID: 29777191
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication.
Chromy D; Mandorfer M; Bucsics T; Schwabl P; Bauer D; Scheiner B; Schmidbauer C; Lang GF; Szekeres T; Ferenci P; Trauner M; Reiberger T
AIDS Patient Care STDS; 2019 May; 33(5):197-206. PubMed ID: 31067123
[TBL] [Abstract][Full Text] [Related]
3. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
Kawagishi N; Suda G; Nakamura A; Kimura M; Maehara O; Suzuki K; Nakamura A; Ohara M; Izumi T; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Miyoshi H; Sakamoto N
PLoS One; 2018; 13(12):e0209615. PubMed ID: 30576386
[TBL] [Abstract][Full Text] [Related]
4. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
[TBL] [Abstract][Full Text] [Related]
5. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a.
Hofer H; Bankl HC; Wrba F; Steindl-Munda P; Peck-Radosavljevic M; Osterreicher C; Mueller C; Gangl A; Ferenci P
Am J Gastroenterol; 2002 Nov; 97(11):2880-5. PubMed ID: 12425563
[TBL] [Abstract][Full Text] [Related]
7. Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection.
Fernandez-Fuertes M; Macías J; Corma-Gómez A; Rincón P; Merchante N; Gómez-Mateos J; Pineda JA; Real LM
Sci Rep; 2020 Apr; 10(1):6736. PubMed ID: 32317646
[TBL] [Abstract][Full Text] [Related]
8. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
[TBL] [Abstract][Full Text] [Related]
9. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
Ogasawara N; Kobayashi M; Akuta N; Kominami Y; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Suzuki F; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2018 Feb; 90(2):313-319. PubMed ID: 28906010
[TBL] [Abstract][Full Text] [Related]
10. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP).
Cespiati A; Petta S; Lombardi R; Di Marco V; Calvaruso V; Bertelli C; Pisano G; Fatta E; Sigon G; Iuculano F; Crapanzano L; Gibilaro G; Francione P; Craxì A; Fargion S; Fracanzani AL
Dig Liver Dis; 2021 Oct; 53(10):1301-1307. PubMed ID: 33214063
[TBL] [Abstract][Full Text] [Related]
11. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.
Castéra L; Hézode C; Roudot-Thoraval F; Lonjon I; Zafrani ES; Pawlotsky JM; Dhumeaux D
Gut; 2004 Mar; 53(3):420-4. PubMed ID: 14960527
[TBL] [Abstract][Full Text] [Related]
12. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
Huang CF; Dai CY; Yeh ML; Huang CI; Lee HC; Lai WT; Liang PC; Lin YH; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2020 Nov; 36(11):920-928. PubMed ID: 32643842
[TBL] [Abstract][Full Text] [Related]
13. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C.
Adinolfi LE; Utili R; Andreana A; Tripodi MF; Marracino M; Gambardella M; Giordano M; Ruggiero G
Dig Dis Sci; 2001 Aug; 46(8):1677-83. PubMed ID: 11508667
[TBL] [Abstract][Full Text] [Related]
14. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C.
Tachi Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Samejima Y; Goto H
Liver Int; 2010 Apr; 30(4):554-9. PubMed ID: 19951380
[TBL] [Abstract][Full Text] [Related]
15. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
[TBL] [Abstract][Full Text] [Related]
16. Serum lipid profile and hepatic steatosis of adult beta-thalassaemia patients with chronic HCV infection.
Siagris D; Kouraklis-Symeonidis A; Christofidou M; Lekkou A; Papadimitriou C; Arvaniti V; Thomopoulos K; Tsamandas A; Zoumbos N; Labropoulou-Karatza C
Eur J Gastroenterol Hepatol; 2005 Mar; 17(3):345-50. PubMed ID: 15716660
[TBL] [Abstract][Full Text] [Related]
17. Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C.
Shousha HI; Abdelaziz RA; Azab SM; Khairy M; Afifi SA; Mehrez MI; Eshra MA; Abdelrahim AY
J Med Virol; 2018 Jun; 90(6):1099-1105. PubMed ID: 29469217
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
Beig J; Orr D; Harrison B; Gane E
Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
[TBL] [Abstract][Full Text] [Related]
20. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
Westin J; Lagging M; Dhillon AP; Norkrans G; Romero AI; Pawlotsky JM; Zeuzem S; Schalm SW; Verheij-Hart E; Negro F; Missale G; Neumann AU; Hellstrand K;
J Viral Hepat; 2007 Jan; 14(1):29-35. PubMed ID: 17212641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]